Trial reportWorld journal of gastroenterology2003
Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders.
Trial report in World journal of gastroenterology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01126853 (A Pilot Study Evaluating the Combination Hepatitis A and B Vaccine), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study Evaluating the Combination Hepatitis A and B Vaccine (Twinrix®) in Healthy Healthcare Workers Who Meet the CDC Definition for Non-responders.
Who cites it
15 citing papers in PubMed.
- Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India.World journal of gastroenterology · 2005Trial
- Four-year follow up of hepatitis C patients vaccinated against hepatitis B virus.World journal of gastroenterology · 2005Trial
- Article
- Article
- Article
- Protective immunity against hepatitis B virus infection in a group of vaccinated Sri Lankan military service men following a complete course of vaccination.Virusdisease · 2019Article
- Factors That Influence the Immune Response to Vaccination.Clinical microbiology reviews · 2019Review
- Seroconverting nonresponder of high-dose intramuscular HBV vaccine with intradermal HBV vaccine: A case report.Medicine · 2017Article
- Decrease in Anti-HBs Antibodies over Time in Medical Students and Healthcare Workers after Hepatitis B Vaccination.BioMed research international · 2017Article
- Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations.PloS one · 2017Article
- Response to hepatitis B vaccination in patients with celiac disease.Digestive diseases and sciences · 2008Article
- Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen.Journal of clinical microbiology · 2008Article
- Article
- Construction of exogenous multiple epitopes of helper T lymphocytes and DNA immunization of its chimeric plasmid with HBV pre-S2/S gene.World journal of gastroenterology · 2004Article
- Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination.Cancer immunology, immunotherapy : CII · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe study was initiated to evaluate the reactogenicity and immunogenicity of a recombinant hepatitis B vaccine in age group >40 years and to study the response of a single booster dose in primary non-responders to the hepatitis B vaccination.
methodsA total of 102 volunteers without markers of hepatitis B infection (negative for HBsAg, anti-HBc antibody, HBeAg and anti-HBs antibody) received 20 microg of recombinant HB vaccine intramuscularly at 0, 1, and 6 months. Anti HBs titers were evaluated by a quantitative Elisa kit at 90 and 210 days. A booster dose of 20 microg HB vaccine was given after 6 months of the 3(rd) vaccine dose to the 15 non-responders and anti-HBs titers were measured after 1 month.
resultsSeroprotection (anti-HBs GMT(3) 10 IU/L) was achieved in 85.3 % (87/102) volunteers. The mean GMT titers of the vaccine responders was 136.1 IU/L. Of the seroprotected individuals, there were 32.4 % (33/102) hyporesponders (anti-HBs titers <10-99 mlU/ml) and 52.9 % (54/102) were responders (anti-HBs titers >100 IU/L). All the non-responders (15/15) responded to a single dose of the booster dose of recombinant HB vaccine and their mean anti-HBs antibody titers were more than 100.5 mIU/ml after the booster dose.
conclusionRecombinant hepatitis B vaccine offers good seroprotection in the age group >40 years and has a good safety profile. A single booster dose after 6 months in primary non-responders leads to good seroprotective anti-HBs antibody titers. However, larger population based studies are needed to evaluate the role of a booster dose in selected group of non-responders and whether such an approach will be cost effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.